Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Deals

Fapon Biotech Partners with Roche Diagnostics at China International Import Expo

Fineline Cube Nov 18, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with Swiss major Roche Diagnostics at...

Company Medical Device

China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel

Fineline Cube Nov 18, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life...

Company Drug

Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency

Fineline Cube Nov 18, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Deals

RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development

Fineline Cube Nov 18, 2022

China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of...

Company

Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth

Fineline Cube Nov 18, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its Q3 2022 financial report, recording...

Company Deals

Marinus Pharmaceuticals Collaborates with Tenacia Biotechnology for Ganaxolone

Fineline Cube Nov 18, 2022

Pennsylvania-based pharma company Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has entered into a collaboration and supply...

Company Legal / IP

Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation

Fineline Cube Nov 18, 2022

US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...

Legal / IP Policy / Regulatory

CDE Issues Trial Rules for NMPA Drug Review Timekeeping Suspension

Fineline Cube Nov 18, 2022

The Center for Drug Evaluation (CDE) has released the “NMPA Drug Review Timekeeping Suspension and...

Company Medical Device

Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...

Company Medical Device

Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...

Company Drug

BeiGene’s Brukinsa Receives EC Approval for CLL Treatment

Fineline Cube Nov 18, 2022

China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...

Company

Zhangjiang AI New Drug R&D Alliance Expands with New Members

Fineline Cube Nov 18, 2022

The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...

Company Deals

Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging

Fineline Cube Nov 17, 2022

Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...

Company Drug

Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs

Fineline Cube Nov 17, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...

Company Deals

Rainsure Scientific Secures Series C1 Funding for Digital PCR Development

Fineline Cube Nov 17, 2022

Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly...

Company Drug

CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication

Fineline Cube Nov 17, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...

Company Deals

Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion

Fineline Cube Nov 17, 2022

Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...

Company Drug

Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE

Fineline Cube Nov 17, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...

Company Drug

CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Nov 17, 2022

China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...

Company Deals

HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology

Fineline Cube Nov 17, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...

Posts pagination

1 … 535 536 537 … 602

Recent updates

  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
  • J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.